StockData

Vir Biotechnology vs Xencor

VIR and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How VIR and XNCR compare

Xencor is the larger company, worth 1.6 times as much as Vir Biotechnology ($2.6B against $1.6B).

Vir Biotechnology grew revenue faster over the last twelve months (1496% versus −28.6% for Xencor).

Vir Biotechnology keeps more of each dollar of sales as profit, with a net margin of −83.0% compared with −156% at Xencor.

Vir Biotechnology scores higher on the StockData Score (11 against 5 for Xencor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricVIRXNCR
Size and price
Market cap$1.6B$2.6B
Share price$9.25$34.50
Change, 1 year64.3%131%
Change, 5 years−74.3%−2.7%
Beta (5Y)0.80−0.05
Employees367260
StockData Score
Total score11 (better)5
Valuation score3 (better)0
Growth score11
Performance score2 (better)1
Health score5 (better)3
Dividend score00
Valuation
P/S5.2× (better)24.4×
P/B1.6× (better)5.1×
FCF yield−13.0%−8.1% (better)
Fair value$13.31$11.73
Margin of safety30.5% (better)−194%
Growth
Revenue growth (TTM)1496% (better)−28.6%
Revenue growth, 5Y average−2.1%0.47% (better)
Profitability
Operating margin−92.4% (better)−206%
Net margin−83.0% (better)−156%
FCF margin−67.1% (better)−198%
Return on equity−26.1% (better)−29.1%
Return on invested capital−55.2%−26.6% (better)
Financial health
Debt / equity0.000.21 (better)
Interest coverage–−8.0×
Current ratio6.046.39 (better)
Altman Z-score2.575.01 (better)
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions86.6%113%
Held by insiders17.1%1.6%
Insider net buying, 12 months−$4.0M (better)−$7.5M
Short interest, % of float12.0%17.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.